234 related articles for article (PubMed ID: 35030632)
1. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.
Ren W; Wang X; Yang M; Wan H; Li X; Ye X; Meng B; Li W; Yu J; Lei M; Xie F; Jiang W; Kimby E; Huang H; Liu D; Li ZM; Wu K; Zhang H; Pan-Hammarström Q
Blood Adv; 2022 May; 6(9):2731-2744. PubMed ID: 35030632
[TBL] [Abstract][Full Text] [Related]
2. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
Ren W; Ye X; Su H; Li W; Liu D; Pirmoradian M; Wang X; Zhang B; Zhang Q; Chen L; Nie M; Liu Y; Meng B; Huang H; Jiang W; Zeng Y; Li W; Wu K; Hou Y; Wiman KG; Li Z; Zhang H; Peng R; Zhu S; Pan-Hammarström Q
Blood; 2018 Jun; 131(24):2670-2681. PubMed ID: 29545328
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.
Cheng CL; Fang WQ; Lin YJ; Yuan CT; Ko BS; Tang JL; Tien HF
J Cancer Res Clin Oncol; 2022 May; 148(5):1211-1222. PubMed ID: 34228224
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
8. Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.
Fernández-Rodríguez C; Rodríguez-Sevilla JJ; Fernández-Ibarrondo L; Sánchez-González B; Gibert J; Bento L; García JF; Sancho JM; Diez-Feijóo R; Camacho L; García-Retortillo M; Gimeno E; Colomo L; Gutiérrez A; Bellosillo B; Salar A
Blood Adv; 2022 Jan; 6(1):82-86. PubMed ID: 34649275
[TBL] [Abstract][Full Text] [Related]
9. Identification of hepatitis B virus aetiologic antigens, HBx and Pre-S2, in diffuse large B-cell lymphoma.
Huang X; Young KH; Guo W; Wang Y; Wang X; Xi Y; Wang L; Bai O
J Viral Hepat; 2020 Sep; 27(9):948-950. PubMed ID: 32281709
[TBL] [Abstract][Full Text] [Related]
10. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.
Horn H; Schmelter C; Leich E; Salaverria I; Katzenberger T; Ott MM; Kalla J; Romero M; Siebert R; Rosenwald A; Ott G
Haematologica; 2011 Sep; 96(9):1327-34. PubMed ID: 21659362
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
Wang F; Xu RH; Luo HY; Zhang DS; Jiang WQ; Huang HQ; Sun XF; Xia ZJ; Guan ZZ
BMC Cancer; 2008 Apr; 8():115. PubMed ID: 18433487
[TBL] [Abstract][Full Text] [Related]
12. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.
Burkhard R; Bhagat G; Cogliatti SB; Rossi D; Gaidano G; Pasqualucci L; Novak U
Hematol Oncol; 2015 Mar; 33(1):23-30. PubMed ID: 24496723
[TBL] [Abstract][Full Text] [Related]
13. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Serological Characterization of Hepatitis B Virus (HBV)-Positive Samples with Very Low or Undetectable Levels of HBV Surface Antigen.
Kuhns MC; Holzmayer V; Anderson M; McNamara AL; Sauleda S; Mbanya D; Duong PT; Dung NTT; Cloherty GA
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696483
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
18. Impact of "a" determinant mutations on detection of hepatitis B surface antigen (HBsAg) in HBV strains from Chinese patients with occult hepatitis B.
Huang X; Ma C; Zhang Q; Shi Q; Huang T; Liu C; Li J; Hollinger FB
J Med Virol; 2017 Oct; 89(10):1796-1803. PubMed ID: 28513915
[TBL] [Abstract][Full Text] [Related]
19. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
